Study of ONL1204 for geographic atrophy in dry AMD
Part of Eyes & vision clinical trials.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have dry age-related macular degeneration with geographic atrophy (an area of cell damage in the back of the eye).
- You have not had any treatment with gene therapy for an eye disease.
- You are not pregnant, planning to become pregnant, or breastfeeding, and you will use effective birth control if needed.
- You are willing to stay on any AREDS2 vitamin supplements you are currently taking or continue not taking them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This trial tests whether a monthly injection of pozelimab into the eye can slow the growth of geographic atrophy (a late form of dry age-related macular degeneration). It may help people who have significant vision loss from this condition.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This study looks at how avacincaptad pegol (brand name Izervay) works in real-world medical practice for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. If your doctor has already decided to treat you with this medicine, you may be able to join.
Hear when a new Geographic Atrophy (GA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.